Prediction of CDK inhibitor efficacy in ER+/HER2-breast cancer using machine learning algorithms

被引：1
|
作者：
Mason, Jeremy [1 ]
Gong, Yutao [1 ]
Amiri-Kordestani, Laleh [1 ]
Wedam, Suparna [1 ]
Gao, Jennifer J. [1 ]
Singh, Harpreet [1 ]
Pazdur, Richard [1 ]
Kuhn, Peter [2 ]
Blumenthal, Gideon [1 ]
Beaver, Julia A. [1 ]
机构：
[1] US FDA, Silver Spring, MD USA
[2] Univ Southern Calif, Los Angeles, CA 90007 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-PD2-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD2-07
引用
收藏
页数：2
相关论文
共 50 条
  • [1] TILs in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Viale, G.
    Curigliano, G.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 3 - 3
  • [2] Discovery of CDK4/6 bifunctional degraders for ER+/HER2-breast cancer
    Majeski, Hannah
    Okano, Akinori
    Pasis, Angela
    Carlson, Casey
    Shakya, Arvind
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah M.
    Liu, Qiao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Estetrol for treatment of advanced ER+/HER2-breast cancer
    Schmidt, Marcus
    Hoenig, Arnd
    Zimmerman, Yvette
    Verhoeven, Carole
    Almstedt, Katrin
    Battista, Marco
    Lenhard, Hans Georg
    Krijgh, Jan
    Bennink, Herjan Coelingh
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [4] Dysregulated expression of repetitive DNA in ER+/HER2-breast cancer
    Yandim, Cihangir
    Karakulah, Gokhan
    [J]. CANCER GENETICS, 2019, 239 : 36 - 45
  • [5] Tumor infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Esposito, A.
    Viale, G.
    Curigliano, G.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [6] Discovery of CDK4/6 bifunctional degraders for ER+/HER2-breast cancer andtriple negative breast cancer
    Majeski, Hannah
    Okano, Akinori
    Pasis, Angela
    Carlson, Casey
    Liu, Qiao
    Shakya, Arvind
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [7] APOBEC driving genomic evolution in ER+/HER2-breast cancer
    Bos, M.
    Smid, M.
    Sleijfer, S.
    Martens, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 138 : S105 - S106
  • [8] Predicting sensitivity to CDK4/6 inhibition in ER+/HER2-breast cancer cell lines
    Bathurst, Lauren
    Liao, Linda
    Crozier, Cheryl
    Bayani, Jane
    Bartlett, John
    Spears, Melanie
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [9] Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2-breast cancer (LEADER).
    Spring, Laura
    Griffin, Colleen
    Isakoff, Steven J.
    Moy, Beverly
    Wander, Seth Andrew
    Shin, Jennifer
    Abraham, Elizabeth
    Habin, Karleen
    Patel, Jaymin M.
    Comander, Amy H.
    Mulvey, Therese Marie
    Bardia, Aditya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Vialel, G.
    Curigliano, G.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 347 - 354
12345